ProQR Therapeutics NV expected to post a loss of 24  cents a share - Earnings Preview

ProQR Therapeutics NV

02/05/2022 19:35

* ProQR Therapeutics NV  PRQR.OQ   PRQR.O  is expected
to show a
rise in quarterly revenue when it reports  results on May 4
(estimated). 
    * The Leiden Zuid-holland-based  company is expected to
report  a
284.9% increase in revenue to €542.76 thousand from €141
thousand a year ago, according to the mean estimate from 5
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for ProQR Therapeutics
NV is
for a loss of 24 cents per share. For the same quarter last
year, the company reported a loss of 25 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 1.1%
in the last three months. ​
    * Wall Street's median 12-month price target for ProQR
Therapeutics NV is $4.5​, above​ its last closing price
of $0.69. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in euros). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.18       -0.19      -0.26     Missed  -40
 Sep. 30 2021  -0.20       -0.21      -0.22     Missed  -7.3
 Jun. 30 2021  -0.22       -0.22      -0.24     Missed  -7.8​
 Mar. 31 2021  -0.25       -0.25      -0.25     Met     -0.1
 ​​Dec.        -0.25       -0.25      -0.26     Missed  -3.6
 31 2020                                                
 Sep. 30 2020  -0.30       -0.30      -0.26     Beat    13.5​
 Jun. 30 2020  -0.29       -0.33      -0.08     Beat    75.6
 Mar. 31 2020  -0.34       -0.34      -0.32     Beat    6.4
 This summary was machine generated May 2 at 18:34 GMT.  All
figures in euros  unless otherwise stated